http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
폐결핵환자에서 기관지폐포세척액 및 말초혈액의 임파구 아형에 관한 연구
한성구(S . K . Han),조상헌(S . H . Cho),김준우(J . W . Kim),김영환(Y . W . Kim),심영수(Y . S . Shim),김건열(K . Y . Kim),한용철(Y . C . Han) 대한내과학회 1988 대한내과학회지 Vol.34 No.3
N/A It is known that the helper T-cell subset of T-lymphocyte is decreased in the peripheral blood of tuberculosis patients. To explain this phenomenon, the compartmentalization theroy, suppressor monocyte and clonal expansion theory and others were proposed. To elucidate these phenomenon, we examined the changes of lymphocyte subsets in bronchoalveolar lavage fluid and peripheral blood of pulmonary tuberculosis patients by double bridge technique of alkaline phosphatase-anti-alkaline phosphatase (APAAP) using monoclonal antibodies, and obtained the following results. 1) Total cell count of bronchoalveolar lavage fluid in pulmonary tuberculosis patients was 28±14.5×106 and showed significantly increased value compared with control group of 16.96±10.75×106(P<0.01). The T-lymphocyte percentage ratio to total cell count was 30.11±17.21% in pulmonary tuberculosis patients and it showed significantly increased ratio compared with 6.85±2.11% of control group (p<0.05). 2) Helper T-cell/suppressor T-cell ratio in the peripheral blood of pulmonary tuberculosis patients was 1.32±0.2 and showed significantly lower value compared with 1.58±0.19 of control group (p<0.05). Total T-lymphocyte and helper T-cells were also decreased but not in the magnitude of statistical significance. Suppressor T-cell showed no difference between pulmonary tuberculosis patients and control group. 3) Total T-lymphocyte (mean 64.84%) and helper T-cells (mean 41.9%) in bronchoalveolar lavage fluid of pulmonary tuberculosis patients were significantly increased than the control group of 53.42% and 32.28%. Helper T-cell/suppressor T-cell ratio was 1.9±0.58 in pulmonary tuberculosis patients and 1.5±0.16 in control group with no significant difference (p>0.05). There was no difference of suppressor T-cells of bronchoalveolar lavage fluid between the two comparing groups. 4) In pulmonary tuberculosis patients, total T- lymphocytes (mean 64.84%) and helper T-cells (mean 41.92%) in the bronchoalveolar lavage fluid were significantly increased than in the peripheral blood (44.92% and 27.00%). And helper T-cell/suppressor T-cell ratio (mean 1.92) was also increased in bronchoalveolar lavage fluid than in the peripheral blood (mean 1.32), but suppressor T-cells showed no difference between the bronchoalveolar lavage fluid and peripheral blood.
특발성 폐섬유화증 환자에서 기관지폐포세척액 소견과 생리-방사선-조직학적 진행도와의 상관관계 및 스테로이드 치료에 대한 예후인자와 구성세포 변화에 관한 연구
조상헌 ( S. H. Cho ),이상도 ( S. D. Lee ),권오정 ( O. J. Kwon ),이춘택 ( C. T. Lee ),정희순 ( H. S. Chung ),한성구 ( S. K. Han ),심영수 ( Y. S. Shim ),김건열 ( K. Y. Kim ),한용철 ( Y. C. Han ),함의근 ( E. K. Ham ) 대한결핵 및 호흡기학회 1989 Tuberculosis and Respiratory Diseases Vol.36 No.4
신기능장애 및 혈액투석환자에서의 Pyrazinamide 의 약력학적 연구
김대중(D . J . Kim),김성권(S . K . Kim),이정상(J . S . Lee),한용철(Y . C . Han),이문호(M . H . Lee),이선희(S . H . Lee),신상구(S . G . Shin),박찬웅(C . W . Park) 대한내과학회 1986 대한내과학회지 Vol.31 No.1
The pharmacokinetics of single oral dose(lgm) of pyrazinamide was studied in 20 patients with various degrees of renal insufficiency including 6 patients on long-term hemodialysis. The average 24 hr urinary recovery of pyrazinamide in patients with creatinine clearance 10 to 30 ml/hr/kg, and patients with creatinine clearance lesser than 10 ml/hr/kg were 7.5 and 0.9% of administered dose respectively. Serum half-life of the drug was slightly, but significantly(p<0.05), prolonged in patients with creatinine clearance lesser than 10 ml/hr/kg(half-life; 11.25±2.55 hr) compared with normal subjects(half-life; 8.21±1.38 hr) previously reported. The mean serm half-life of pyrazinamide in patients on longterm hemodialysis was 12.26±2.92 hr. The half-life fell to 3.52±1.17 hr during hemodialysis. It was estimated that approximately 41% of drug in the body was removed into dialysate during 4 hr dialysis. The mean dialysance of pyrazinamide was 91.40±2.83 ml/min. From the observed pharmacokinetics of pyrazinamide in patients with impaired renal function, it is suggested that adjustment of dosage regimen may not be required for patients just with impaired renal function. However, replacement of dialysed fraction of pyrazinamide would be required for the maintenance of adequate serum level.